Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee
Organogenesis Holdings Inc. - Class A (ORGO)
Last organogenesis holdings inc. - class a earnings: 3/9 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis RMAT Designation Enables Closer FDA Interactions to Support Accelerated Approval CANTON, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has granted ReNu®, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis (OA), Regenerative Medicine Advanced Therapy (RMAT) designation. The FDA created the RMAT designation program to expedite development and review of regenerative medicine therapies intended to treat, modify, reverse or cure a serious or life-threatening disease or
Show less
Read more
Impact Snapshot
Event Time:
ORGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGO alerts
High impacting Organogenesis Holdings Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ORGO
News
- Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024GlobeNewswire
- Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case [Yahoo! Finance]Yahoo! Finance
- Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud CaseGlobeNewswire
- Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Organogenesis Holdings Inc. (NASDAQ: ORGO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $5.00 price target on the stock.MarketBeat
ORGO
Earnings
- 2/29/24 - Beat
ORGO
Sec Filings
- 4/3/24 - Form 8-K
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- ORGO's page on the SEC website